-Reuters Citing Japan Coast Guard
FDA Eases Partial Hold On Avidity Biosciences’ Investigational Drug Study In Type Of Dystrophy
The FDA has eased the partial clinical hold on Avidity Biosciences Inc's (NASDAQ: RNA) AOC 1001, allowing Avidity to double the number of participants in the MARINA Open-Label Extension (MARINA-OLE) study